Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.
Vico Therapeutics has raised $12.3M in total funding. The most recent round was Series B. The last funding was announced in June 2024.
Vico Therapeutics's investors include Polaris Partners, EQT Life Sciences, Eurazeo, Kurma Partners, Pureos Bioventures.
Vico Therapeutics is headquartered in Leiden, The Netherlands.
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.
Vico Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vico Therapeutics — Funding & Investors." VCBacked, June 24, 2024, https://www.vcbacked.co/company/vico-therapeutics. Accessed August 14, 2026.
VCBacked. (2024). Vico Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/vico-therapeutics
{{cite web |title=Vico Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/vico-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated